Literature DB >> 32584527

Clozapine and COVID-19.

Gary Remington1, Valerie Powell1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32584527     DOI: 10.1503/jpn.2045301

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  2 in total

1.  Clozapine and COVID-19: The authors respond.

Authors:  Dan Siskind; William G Honer; Scott Clark; Christoph U Correll; Alkomiet Hasan; Oliver Howes; John M Kane; Deanna L Kelly; Robert Laitman; Jimmy Lee; James H MacCabe; Nick Myles; Jimmi Nielsen; Peter F Schulte; David Taylor; Helene Verdoux; Amanda Wheeler; Oliver Freudenreich
Journal:  J Psychiatry Neurosci       Date:  2020-07-01       Impact factor: 6.186

Review 2.  Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.

Authors:  Ana Miruna Dragoi; Ioana Radulescu; Bogdana Adriana Năsui; Anca Lucia Pop; Valentin Nicolae Varlas; Simona Trifu
Journal:  Brain Sci       Date:  2020-11-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.